Cancer Blog
- Dr. Robert Nagourney -

These results confirm that the majority of cancer patients in the US today do not respond to the NCCN guideline therapies that their physici

Your life is too important to rely on statistical averages. Get the personalized approach you deserve.

Biliary tract cancer afflicts 8,000 patients in the US each year. It is separated into intrahepatic and and extrahepatic.

I’ve long held that there are no bad cancers, just cancers that we can or cannot treat.

Treatments should really be given more selectively, i.e. “give this chemotherapy only to those people who will benefit from it,” She said.

I received a video from an episode of Americas Got Talent, the popular TV program that features up-and-coming performers.

Genomic findings are a first step. They find targets. The question the patient wants to answer is “Can I hit the target?”

Cancer patients deserve better. Every patient is unique. Their treatment should be as well.

Daniel Werner, a dedicated nurse and a loving fiancé and father, faced the grim reality of a stage 4 colon cancer diagnosis in December 2021

The NAPOLI-3 trail trial median survival of 11.1 months is exactly the same as the original FOLFIRINOX regimen from 13 years ago.

One of the critical advantages of Functional Profiling over traditional genomic testing is its focus on the actual response of cancer cells.

Cancer patients approach their diagnosis with a sense of terror. One day they are fine and feeling well and the next, a terminal diagnosis.

Rising corporate influence and focus on reimbursement in medicine now discourage doctors from straying from strict treatment guidelines.

Cancer therapy can be really expensive. But here's the kicker, Functional Profiling costs way less than receiving the incorrect treatment.

Although she showed some response, her disease persisted and she was being considered for surgery to remove the residual tumor...

George Brown is alive today because our laboratory analysis identified a simple 2 drug combination that now one else thought to give him.

This patient had recurrent breast cancer that upon biopsy proved to be triple negative.

Personalized treatment means more cured patients. More people survive cancer when our Functional Profiling system is used before treatment.

However, a new dilemma has arisen; the failure of surgeons to comply with Pancreatic Cancer patient’s wishes to have tissue submitted.

There has been talk of improved survival in cancer, most progress has reflected screening, early diagnosis, improved staging, and support.